查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081907

獸用疫苗市場：2026-2032年全球市場預測（依產品類型、動物類型、給藥途徑、價態、儲存條件、疾病類型及分銷管道分類）

Veterinary Vaccines Market by Product Type, Animal Type, Route Of Administration, Valency, Storage Requirement, Disease Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸用疫苗市場規模將達到 241.5 億美元，複合年成長率為 6.99%。

主要市場統計數據
基準年 2025 150.5億美元
預計年份：2026年 160.4億美元
預測年份：2032年 241.5億美元
複合年成長率 (%) 6.99%

獸用疫苗執行摘要

動物疫苗在動物健康、食品安全、通用感染疾病預防和永續畜牧業生產力方面發揮著至關重要的作用。它們保護伴侶動物、家禽、豬、牛、養殖魚類和其他牲畜免受病毒、細菌和寄生蟲疾病的侵害，同時有助於減少治療性抗生素的使用。對有效動物疫苗的需求受到以下因素的影響：畜牧業生產的集約化、寵物飼養量的增加、跨境動物貿易、氣候變遷導致的疾病分佈變化，以及人們對「同一健康」原則（將動物、人類和環境健康聯繫起來）的認知不斷提高。

獸用疫苗產業的變革性變化

隨著動物衛生系統不斷適應不斷變化的疾病生態系統、日益嚴格的生物安全要求以及全球範圍內減少抗生素使用的趨勢，獸用疫苗行業正在經歷變革。政府部門和生產者越來越認知到疫苗接種的重要性，將其視為預防生產損失、控制疾病傳播和支持合理使用抗生素的第一線手段。這在集約化家禽、生豬和牛養殖系統中尤其關鍵，因為感染疾病的爆發會迅速擾亂供應鏈和貿易流通。

人工智慧對獸用疫苗的累積影響

人工智慧（AI）對獸用疫苗的影響日益顯著，涵蓋了從疫苗發現、研發、生產、分銷到接種後監測的各個環節。在研發領域，AI驅動的免疫資訊學能夠進行病原體基因組篩檢、抗原候選物鑑定、蛋白質結構建模，並優先篩選可能觸發保護性免疫反應的抗原決定基。雖然這些方法不能取代實驗室檢驗或動物攻毒試驗，但它們可以改善早期決策，並減少評估低成功率候選疫苗所花費的時間。

獸用疫苗的關鍵區域見解

亞太地區畜牧業至關重要，因為該地區畜牧業存欄量龐大，家禽和生豬養殖系統高度密集，水產養殖業蓬勃發展，且持續面臨跨國動物疫病的威脅。儘管該地區各國已加強了禽流感、口蹄疫、豬瘟、狂犬病和其他重點疫病的疫苗接種和監測體系，但由於都市區寵物飼養量的增加，伴侶動物的疫苗接種率也不斷提高。由於該地區情況各異，疫苗接種率也存在差異：一些市場擁有完善的低溫運輸和管理體制，而另一些市場則面臨農村地區和小規模疫苗取得方面的挑戰。

獸用疫苗領域領先研究小組的研究結果

東協獸用疫苗的優先事項受到高密度畜牧養殖、小規模農戶、區域內牲畜流動以及禽流感、口蹄疫、豬瘟、狂犬病和新發通用感染疾病等持續風險的影響。該組織的動物衛生議程日益強調疫苗接種與監測、檢測能力和糧食安全之間的協調。由於疾病威脅往往跨越國界，因此標準的統一和跨境協調仍然至關重要。

各國獸用疫苗概況

在美國，獸用疫苗環境高度發達，這得益於商業性畜牧生產、伴侶動物保健、聯邦和州級疾病監測以及健全的生物安全計劃。重點工作包括狂犬病預防、家禽疫苗接種、豬病管理、牛呼吸道和生殖系統疾病控制以及應對外來動物疾病的準備工作。在加拿大，重點工作包括畜牧健康、伴侶動物免疫接種、合理使用抗生素以及對影響牛、豬、家禽、野生動物和貿易的疾病進行監測。墨西哥獸用疫苗的重點工作包括狂犬病控制、牛健康管理、家禽和豬病預防以及與食品生產和區域貿易相關的疫苗接種計劃。

獸用疫苗產業領導者使用的實用建議

產業供應商應優先考慮能夠應對高負擔地方性疾病、新發通用感染疾病風險以及滿足特定生產系統需求的疫苗組合。投資重組疫苗、載體疫苗、標記疫苗、黏膜疫苗和熱穩定疫苗技術可以提高疫苗的差異化程度、現場效用和應對疫情的準備能力。同時，在那些已證實有效、監管管道完善且部署成本效益高的領域，傳統疫苗平台仍然至關重要。

調查方法

本執行摘要採用系統性的二手資訊來源，內容涉及獸用疫苗、動物健康、通用感染疾病預防和生技藥品研究途徑。該調查方法強調來自獸醫公共衛生機構、動物健康組織、監管機構、同行評審的科學文獻、國家疾病控制計畫以及經認證的流行病學監測資源的證據。

結論

隨著動物健康系統面臨感染疾病威脅、通用感染疾病風險、食品安全需求、抗生素抗藥性問題以及不斷變化的生產模式，獸用疫苗的重要性日益凸顯。這一領域正透過整合成熟的疫苗平台、新一代生技藥品、數位化監測、人工智慧分析以及加強以「同一健康」為核心的各項措施的協調，不斷發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 獸用疫苗市場：依產品類型分類

  • 去活化疫苗
  • 減毒活疫苗
  • 次單位疫苗和重組疫苗
  • 病毒載體疫苗

第8章：獸用疫苗市場：依動物類型分類

  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 豬

第9章 獸用疫苗市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第10章 獸用疫苗市場：依價態分類

  • 單價疫苗
  • 多價疫苗

第11章 獸用疫苗市場：依儲存條件分類

  • 冷藏
  • 冰凍
  • 耐溫性

第12章 獸用疫苗市場：依疾病類型分類

  • 細菌感染疾病
    • 梭狀菌感染
    • 大腸桿菌
    • 鉤端螺旋體病
    • 巴斯德氏菌
  • 黴菌感染疾病
  • 寄生蟲感染疾病
    • 體外寄生蟲
    • 體內寄生蟲
  • 病毒感染疾病
    • 禽流感病毒
    • 牛病毒性腹瀉病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 豬繁殖與呼吸綜合症病毒（PRRSV）
    • 狂犬病毒

第13章 獸用疫苗市場：依通路分類

  • 網路藥房
  • 零售藥房
  • 動物診所

第14章 獸用疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 獸用疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 獸用疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Aptimmune Biologics, Inc.
  • Arko Corp.
  • Bimeda Biologicals Inc
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private Limited
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Limited
  • Hipra SA
  • Huvepharma, Inc.
  • Indian Immunologicals Ltd.
  • Jinyu Bio-technology Co., Ltd.
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Pfizer, Inc.
  • Phibro Animal Health Corporation
  • SAN Group BIoTech Germany GmbH
  • Seppic by Air Liquide Healthcare
  • SK Bioscience
  • Vaxine Pty Ltd.
  • Vaxxinova
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-4316E4E89380

The Veterinary Vaccines Market is projected to grow by USD 24.15 billion at a CAGR of 6.99% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.05 billion
Estimated Year [2026] USD 16.04 billion
Forecast Year [2032] USD 24.15 billion
CAGR (%) 6.99%

Veterinary Vaccines Executive Summary

Veterinary vaccines are central to animal health, food security, zoonotic disease prevention, and sustainable livestock productivity. They help protect companion animals, poultry, swine, cattle, aquaculture species, and other livestock from viral, bacterial, and parasitic diseases while reducing the need for therapeutic antimicrobials. Demand for effective animal vaccines is being shaped by intensified livestock production, expanding pet ownership, cross-border animal trade, climate-driven disease range shifts, and heightened awareness of One Health principles linking animal, human, and environmental health.

The veterinary vaccines landscape includes live attenuated, inactivated, recombinant, subunit, toxoid, conjugate, DNA, RNA, and vector-based platforms. Core use cases span preventive immunization against diseases such as rabies, foot-and-mouth disease, avian influenza, Newcastle disease, classical swine fever, porcine reproductive and respiratory syndrome, bovine respiratory disease, brucellosis, and leptospirosis. Regulatory oversight, cold-chain reliability, strain matching, pharmacovigilance, and field-level vaccination compliance remain decisive factors in vaccine effectiveness. As animal disease surveillance becomes more integrated with digital reporting and genomic epidemiology, veterinary vaccination strategies are moving from reactive outbreak response toward risk-based, data-informed prevention.

Transformative Shifts in the Veterinary Vaccines Landscape

The veterinary vaccines industry is undergoing transformative change as animal health systems adapt to evolving disease ecology, stricter biosecurity expectations, and the global push to reduce antimicrobial use. Public authorities and producers increasingly recognize vaccination as a frontline tool for preventing production losses, limiting disease transmission, and supporting responsible antibiotic stewardship. This is particularly relevant in intensive poultry, swine, and cattle systems where infectious disease outbreaks can rapidly disrupt supply chains and trade flows.

Innovation is shifting vaccine development toward recombinant antigen design, viral vectors, marker vaccines compatible with differentiating infected from vaccinated animals, and next-generation nucleic acid platforms. These approaches can support faster strain updates and more targeted immune responses than many traditional platforms, although practical adoption depends on stability, cost, regulatory acceptance, and administration feasibility. At the same time, oral, intranasal, in ovo, and mass-application delivery methods are gaining importance because ease of administration influences coverage rates in large herds and flocks.

Another major shift is the growing connection between vaccination, surveillance, and traceability. Disease reporting platforms, farm management systems, and laboratory networks are enabling more timely identification of emerging threats. Governments and industry stakeholders are also strengthening preparedness for transboundary animal diseases, including avian influenza, African swine fever, foot-and-mouth disease, and rabies, where coordinated vaccination policy, diagnostics, movement control, and biosecurity must work together.

Cumulative Impact of Artificial Intelligence on Veterinary Vaccines

Artificial intelligence is increasingly influencing veterinary vaccines across discovery, development, manufacturing, distribution, and post-vaccination monitoring. In research and development, AI-supported immunoinformatics can help screen pathogen genomes, identify candidate antigens, model protein structures, and prioritize epitopes with potential to trigger protective immune responses. These methods do not replace laboratory validation or animal challenge studies, but they can improve early-stage decision-making and reduce time spent evaluating low-probability candidates.

In disease surveillance, AI models can analyze veterinary laboratory results, animal movement data, climate variables, syndromic reports, and production anomalies to detect outbreak signals earlier. For vaccine programs, these tools can support risk-based targeting by identifying areas or production systems with elevated exposure risk. In manufacturing and quality systems, machine learning can assist process monitoring, deviation detection, batch consistency analysis, and predictive maintenance, all of which are important for biologics where reliability and compliance are critical.

AI also strengthens field implementation. Digital vaccination records, image-based animal identification, automated reminders, and analytics dashboards can improve adherence to immunization schedules in livestock and companion animals. However, responsible adoption requires high-quality datasets, transparent validation, cybersecurity safeguards, and clear governance around data ownership. The cumulative impact of AI is therefore best understood as an enabling layer that supports faster insight, better targeting, and improved vaccine program performance rather than as a substitute for veterinary expertise and regulatory evidence.

Key Regional Insights for Veterinary Vaccines

Asia-Pacific is a critical region for veterinary vaccines because of its large livestock populations, dense poultry and swine production systems, expanding aquaculture activity, and recurring exposure to transboundary animal diseases. Countries across the region have strengthened vaccination and surveillance for avian influenza, foot-and-mouth disease, classical swine fever, rabies, and other priority diseases, while companion animal vaccination is rising alongside urban pet ownership. The region's diversity creates uneven adoption patterns, with advanced cold-chain and regulatory systems in some markets and access challenges in rural or smallholder settings in others.

North America is characterized by established veterinary care infrastructure, strong companion animal vaccination compliance, commercial livestock health programs, and integrated disease surveillance. Rabies control, bovine respiratory disease prevention, swine and poultry vaccination protocols, and preparedness for foreign animal diseases remain important priorities. Veterinary vaccines are closely linked to food safety, biosecurity, and antimicrobial stewardship initiatives across production systems.

Latin America's veterinary vaccine demand is shaped by cattle production, poultry and swine expansion, and the region's long-standing focus on foot-and-mouth disease control. Brazil and Mexico play important roles in regional animal protein supply chains, while rabies, brucellosis, leptospirosis, and clostridial diseases remain relevant targets. Vaccination policies often interact with export requirements, official disease status, and farm-level biosecurity investments.

Europe maintains rigorous animal health regulation, pharmacovigilance expectations, and coordinated surveillance for zoonotic and transboundary diseases. The region emphasizes antimicrobial reduction, animal welfare, and traceable livestock production, supporting preventive vaccination where epidemiologically justified. Avian influenza preparedness, bluetongue control, rabies prevention in at-risk areas, and livestock disease management are prominent themes.

The Middle East faces veterinary vaccine needs linked to ruminant health, poultry production, camel health, and cross-border animal movement. Foot-and-mouth disease, peste des petits ruminants, brucellosis, rabies, and poultry diseases are important concerns, and vaccination programs are often aligned with import controls, food security strategies, and regional disease surveillance. Climate stress and animal trade routes add complexity to prevention planning.

Africa has substantial unmet need for veterinary vaccination due to the burden of livestock diseases affecting livelihoods, food security, and public health. Priority areas include peste des petits ruminants, contagious bovine pleuropneumonia, foot-and-mouth disease, Newcastle disease, rabies, brucellosis, and lumpy skin disease. Progress depends on vaccine availability, affordability, cold-chain capacity, community-level delivery, and sustained public-private coordination, especially in pastoral and smallholder production systems.

Key Group Insights for Veterinary Vaccines

ASEAN veterinary vaccine priorities are influenced by dense animal production, smallholder farming, regional animal movement, and persistent risks from avian influenza, foot-and-mouth disease, classical swine fever, rabies, and emerging zoonoses. The group's animal health agenda increasingly links vaccination with surveillance, laboratory capacity, and food security. Harmonization of standards and cross-border coordination remain important because disease threats often extend beyond national boundaries.

The GCC's veterinary vaccine needs reflect food security planning, intensive poultry development, ruminant health, camel populations, and reliance on animal imports. Vaccination strategies in the group are closely tied to border inspection, quarantine, disease monitoring, and prevention of foot-and-mouth disease, peste des petits ruminants, brucellosis, rabies, and poultry pathogens. Hot climates and logistics requirements make cold-chain performance and field administration planning especially important.

The European Union applies a highly structured regulatory and surveillance framework that supports evidence-based vaccine authorization, monitoring, and use. Animal vaccination strategies are shaped by disease status rules, movement controls, antimicrobial reduction policies, and coordinated response planning for avian influenza, bluetongue, rabies, and other regulated diseases. The group's emphasis on traceability and pharmacovigilance supports high confidence in vaccine quality and safety.

BRICS countries represent diverse veterinary vaccine conditions, ranging from large commercial livestock sectors to extensive smallholder systems. China, India, Brazil, Russia, and South Africa face significant animal health priorities involving foot-and-mouth disease, avian influenza, swine diseases, brucellosis, rabies, and endemic livestock infections. Their collective importance lies in large animal populations, animal protein production, domestic biologics capacity, and the need for scalable immunization programs.

G7 countries generally have mature animal health governance, advanced veterinary services, strong companion animal vaccination practices, and established biologics regulation. Their priorities include biosecurity, pandemic preparedness for zoonotic and animal-origin threats, antimicrobial stewardship, and resilient food supply chains. Veterinary vaccines in these countries are increasingly integrated with diagnostics, digital records, and risk-based surveillance.

NATO member countries overlap substantially with high-income veterinary health systems but also include varied livestock structures and regional disease risks. Veterinary vaccine relevance within this group extends beyond agriculture to biosecurity, food supply resilience, working animals, and preparedness for deliberate or accidental biological threats affecting animals. Coordinated surveillance and emergency response capacity strengthen vaccination planning for high-consequence animal diseases.

Key Country Insights for Veterinary Vaccines

The United States has a highly developed veterinary vaccine environment supported by commercial livestock production, companion animal healthcare, federal and state disease surveillance, and strong biosecurity programs. Priorities include rabies prevention, poultry vaccination, swine disease management, cattle respiratory and reproductive disease control, and preparedness for foreign animal diseases. Canada emphasizes livestock health, companion animal immunization, antimicrobial stewardship, and surveillance for diseases affecting cattle, swine, poultry, wildlife, and trade. Mexico's veterinary vaccine priorities include rabies control, cattle health, poultry and swine disease prevention, and vaccination programs linked to food production and regional trade.

Brazil is a major animal protein producer where vaccination is closely tied to cattle, poultry, swine, and companion animal health, with foot-and-mouth disease policy, rabies prevention, clostridial disease control, and poultry biosecurity remaining important. The United Kingdom maintains strong companion animal vaccination practices, livestock disease monitoring, and biosecurity planning, with attention to avian influenza, bovine diseases, sheep health, and regulatory oversight. Germany's veterinary vaccine landscape is shaped by advanced animal health infrastructure, intensive livestock systems, companion animal care, and EU-aligned regulation. France combines robust livestock vaccination practices, poultry and ruminant health programs, and strong surveillance for zoonotic and regulated diseases.

Russia faces significant veterinary vaccine needs across large cattle, poultry, swine, and companion animal populations, with attention to avian influenza, rabies, brucellosis, foot-and-mouth disease, and other endemic or transboundary threats. Italy's priorities include companion animal vaccination, cattle and small ruminant health, poultry disease prevention, and regional surveillance for vector-borne and zoonotic infections. Spain has notable livestock and companion animal vaccine use, with swine, poultry, ruminant, and rabies-related prevention supported by veterinary services and EU regulatory standards.

China has one of the world's largest livestock populations, making veterinary vaccines essential for poultry, swine, cattle, sheep, aquaculture, and companion animals. National attention to avian influenza, foot-and-mouth disease, rabies, swine diseases, and food security has strengthened vaccine development and disease control capacity. India's priorities include foot-and-mouth disease, brucellosis, peste des petits ruminants, classical swine fever, rabies, and poultry diseases, with vaccination playing a major role in supporting smallholders, dairy systems, and public health.

Japan maintains a controlled and highly regulated veterinary vaccine environment with strong companion animal care, livestock disease surveillance, and emphasis on biosecurity. Australia's animal health system benefits from geographic biosecurity, structured surveillance, and vaccination programs for livestock and companion animals, with continued focus on preparedness for exotic disease incursions and endemic livestock conditions. South Korea emphasizes high-density livestock health, companion animal vaccination, and preparedness for avian influenza, foot-and-mouth disease, African swine fever control measures, and other high-impact animal disease risks.

Actionable Recommendations for Veterinary Vaccine Leaders

Industry vendors should prioritize vaccine portfolios that align with high-burden endemic diseases, emerging zoonotic risks, and production-system-specific needs. Investment in recombinant, vector-based, marker, mucosal, and thermostable vaccine technologies can improve differentiation, field utility, and outbreak readiness. At the same time, traditional vaccine platforms remain important where they deliver proven protection, established regulatory pathways, and cost-effective deployment.

Strengthening surveillance partnerships is essential. Vaccine developers, animal health authorities, laboratories, veterinarians, and producers should integrate diagnostic data, pathogen sequencing, field effectiveness monitoring, and adverse event reporting to refine strain selection and vaccination protocols. Cold-chain resilience, last-mile distribution, and training for vaccinators should receive the same strategic attention as product innovation, particularly in rural, smallholder, and tropical settings.

Vendors should also embed antimicrobial stewardship and One Health value propositions into veterinary vaccine strategies. Demonstrating reductions in disease incidence, mortality, treatment frequency, and outbreak-related disruption can support adoption by producers and policymakers. Digital vaccination records, AI-enabled risk analytics, and farm-level decision tools can improve compliance and traceability when designed with practical workflows and data governance in mind.

Research Methodology

This executive summary is developed through a structured secondary research approach using publicly available and institutionally recognized sources relevant to veterinary vaccines, animal health, zoonotic disease prevention, and biologics regulation. The methodology emphasizes evidence from veterinary public health agencies, animal health organizations, regulatory authorities, peer-reviewed scientific literature, national disease control programs, and recognized epidemiological surveillance resources.

The analysis focuses on qualitative, data-backed indicators such as disease burden, vaccination policy priorities, regulatory frameworks, livestock and companion animal health dynamics, biosecurity needs, antimicrobial stewardship relevance, and regional animal production characteristics. Information is synthesized to identify strategic themes across technology platforms, disease targets, delivery systems, regional conditions, and adoption enablers. No market sizing, market estimation, market share, or forecasting assumptions are applied.

Quality control involves cross-checking disease and vaccination themes across multiple credible references, prioritizing recent and authoritative materials, and avoiding unsupported claims. Regional, group, and country insights are presented as narrative interpretations of verified animal health trends rather than numerical projections.

Conclusion

Veterinary vaccines are becoming increasingly important as animal health systems confront infectious disease pressure, zoonotic risk, food security demands, antimicrobial resistance concerns, and changing production models. The sector is advancing through a combination of proven vaccine platforms, next-generation biologics, digital surveillance, AI-enabled analytics, and stronger policy alignment around One Health.

Future competitiveness will depend on the ability to deliver safe, effective, accessible, and field-adapted vaccines across diverse animal populations and geographies. Stakeholders that combine scientific innovation with surveillance integration, regulatory readiness, cold-chain execution, and clear evidence of farm-level value will be best positioned to support resilient animal health systems and sustainable protein supply chains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Veterinary Vaccines Market, by Product Type

  • 7.1. Inactivated Vaccines
  • 7.2. Live Attenuated Vaccines
  • 7.3. Subunit & Recombinant Vaccines
  • 7.4. Viral Vector Vaccines

8. Veterinary Vaccines Market, by Animal Type

  • 8.1. Companion Animals
    • 8.1.1. Cats
    • 8.1.2. Dogs
  • 8.2. Livestock Animals
    • 8.2.1. Cattle
    • 8.2.2. Poultry
    • 8.2.3. Sheep
    • 8.2.4. Swine

9. Veterinary Vaccines Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Topical

10. Veterinary Vaccines Market, by Valency

  • 10.1. Monovalent
  • 10.2. Multivalent

11. Veterinary Vaccines Market, by Storage Requirement

  • 11.1. Refrigerated
  • 11.2. Frozen
  • 11.3. Thermostable

12. Veterinary Vaccines Market, by Disease Type

  • 12.1. Bacterial Infections
    • 12.1.1. Clostridial
    • 12.1.2. E. Coli
    • 12.1.3. Leptospirosis
    • 12.1.4. Pasteurella
  • 12.2. Fungal Infections
  • 12.3. Parasitic Infections
    • 12.3.1. Ectoparasites
    • 12.3.2. Endoparasites
  • 12.4. Viral Infections
    • 12.4.1. Avian Influenza Virus
    • 12.4.2. Bovine Viral Diarrhea Virus (BVDV)
    • 12.4.3. Foot-and-Mouth Disease Virus (FMDV)
    • 12.4.4. Newcastle Disease Virus
    • 12.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 12.4.6. Rabies Virus

13. Veterinary Vaccines Market, by Distribution Channel

  • 13.1. Online Pharmacies
  • 13.2. Retail Pharmacies
  • 13.3. Veterinary Clinics

14. Veterinary Vaccines Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Veterinary Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Aptimmune Biologics, Inc.
  • 18.2. Arko Corp.
  • 18.3. Bimeda Biologicals Inc
  • 18.4. Biogenesis Bago S.A.
  • 18.5. Boehringer Ingelheim International GmbH
  • 18.6. Brilliant Bio Pharma Private Limited
  • 18.7. Ceva Sante Animale
  • 18.8. Dechra Pharmaceuticals PLC
  • 18.9. Elanco Animal Health Incorporated
  • 18.10. Endovac Animal Health
  • 18.11. Hester Biosciences Limited
  • 18.12. Hipra S.A.
  • 18.13. Huvepharma, Inc.
  • 18.14. Indian Immunologicals Ltd.
  • 18.15. Jinyu Bio-technology Co., Ltd.
  • 18.16. Kemin Industries, Inc.
  • 18.17. Merck & Co., Inc.
  • 18.18. Neogen Corporation
  • 18.19. Pfizer, Inc.
  • 18.20. Phibro Animal Health Corporation
  • 18.21. SAN Group Biotech Germany GmbH
  • 18.22. Seppic by Air Liquide Healthcare
  • 18.23. SK Bioscience
  • 18.24. Vaxine Pty Ltd.
  • 18.25. Vaxxinova
  • 18.26. Virbac S.A.
  • 18.27. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VETERINARY VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VETERINARY VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VETERINARY VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL VETERINARY VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SUBUNIT & RECOMBINANT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SUBUNIT & RECOMBINANT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SUBUNIT & RECOMBINANT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CATS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CATS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CATS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVESTOCK ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVESTOCK ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVESTOCK ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CATTLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CATTLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CATTLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POULTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POULTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POULTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SHEEP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHEEP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SHEEP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SWINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SWINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SWINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONOVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONOVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONOVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTIVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MULTIVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL REFRIGERATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL REFRIGERATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL REFRIGERATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FROZEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FROZEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FROZEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THERMOSTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THERMOSTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THERMOSTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLOSTRIDIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CLOSTRIDIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLOSTRIDIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL E. COLI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL E. COLI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL E. COLI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LEPTOSPIROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LEPTOSPIROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LEPTOSPIROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PASTEURELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PASTEURELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PASTEURELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ECTOPARASITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ECTOPARASITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ECTOPARASITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENDOPARASITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOPARASITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENDOPARASITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AVIAN INFLUENZA VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AVIAN INFLUENZA VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AVIAN INFLUENZA VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOVINE VIRAL DIARRHEA VIRUS (BVDV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BOVINE VIRAL DIARRHEA VIRUS (BVDV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOVINE VIRAL DIARRHEA VIRUS (BVDV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL FOOT-AND-MOUTH DISEASE VIRUS (FMDV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL FOOT-AND-MOUTH DISEASE VIRUS (FMDV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL FOOT-AND-MOUTH DISEASE VIRUS (FMDV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEWCASTLE DISEASE VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEWCASTLE DISEASE VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEWCASTLE DISEASE VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RABIES VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RABIES VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RABIES VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GCC VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. GCC VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 227. GCC VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. G7 VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. G7 VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 266. G7 VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 269. G7 VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. NATO VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. NATO VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 278. NATO VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 279. NATO VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. NATO VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 282. NATO VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. CANADA VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. CANADA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CANADA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. CANADA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 302. CANADA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 303. CANADA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. CANADA VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 305. CANADA VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. MEXICO VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 315. MEXICO VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. MEXICO VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. BRAZIL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. BRAZIL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. BRAZIL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. BRAZIL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 328. BRAZIL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 329. BRAZIL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. BRAZIL VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 331. BRAZIL VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 332. BRAZIL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. BRAZIL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 334. BRAZIL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED KINGDOM VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 350. GERMANY VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 351. GERMANY VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 352. GERMANY VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 353. GERMANY VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 354. GERMANY VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 355. GERMANY VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 356. GERMANY VETERINARY VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 357. GERMANY VETERINARY VACCINES MARKET SIZE, BY STORAGE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 358. GERMANY VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)